[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Raimondo, 2004 - Google Patents

37th Annual Meeting of the Italian Association for the Study of the Liver (AISF), Rome, 18–20 February 2004

Raimondo, 2004

Document ID
1442237462361608102
Author
Raimondo M
Publication year
Publication venue
Digestive and Liver Disease

External Links

Continue reading at scholar.google.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Oberbauer et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation
Chandra et al. Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in patients with chronic hepatitis C virus: Preliminary results from a randomized, double-blind, placebo-controlled, ascending multiple dose study
Gao et al. Pathological roles of interleukin-22 in the development of recurrent hepatitis C after liver transplantation
Raimondo 37th Annual Meeting of the Italian Association for the Study of the Liver (AISF), Rome, 18–20 February 2004
Stieger et al. The 22nd Conference of the Asian Pacific Association for the Study of the Liver
Dubernard et al. THE INTERNATIONAL REGISTRY ON HAND AND COMPOSITE TISSUE ALLOGRAFT
Olthoff et al. COMPLICATIONS AFTER LIVING LIVER DONATION: A PROSPECTIVE, MULTICENTER REPORT
Eljaafari et al. Isolation of skin T lymphocytes from hand transplant, and evaluation of their allo-response against donor APCs
Suda et al. HEPATOCELLULAR CARCINOMA. Yasunari Nakamoto, Takashi
Jardine PHASE III PROSPECTIVE, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CONCENTRATION CONTROLLED RAPAMUNE (SIROLIMUS) WITH CICLOSPORIN DOSE MINIMISATION OR ELIMINATION IN DE NOVO RENAL ALLOGRAFT RECIPIENTS AT 12 MONTHS
Kahan et al. A concentration-controlled regimen of high sirolimus exposure supports functional recovery of human renal allografts from deceased donors
Kandaswamy et al. A prospective, randomized study of cyclosporine (csa)/mycophenolate mofetil (mmf) versus tacrolimus (tac)/sirolimus (sir) with rapid discontinuation of prednisone (p)
Petruzzo et al. Long-term results of two cases of bilateral hand transplantation: Lyon experience
Nart et al. HBV cccDNA evaluation in HBV-core antibody (HBcAb)-positive liver transplant donors
Shafi et al. Taeheon Lee, Byung Ik Kim, Yong Kyun Cho, Woo Kyu Jeon, Hong Joo Kim; Kangbuk Samsung Hospital, Seoul, Korea (the Republic of)
Webster et al. TOR-INHIBITORS (SIROLIMUS AND EVEROLIMUS) FOR PRIMARY IMMUNOSUPPRESSION OF RENAL TRANSPLANT RECIPIENTS: A META-ANALYSIS RANDOMISED TRIALS.
Zoet et al. HLA-Cw specific antibodies and kidney transplantation
Ishida et al. NEED FOR PREOPERATIVE ANTIBODY ELIMINATION IN PANEL REACTIVE ANTIBODY ASSAY (PRA) POSITIVE PATIENTS; A CLINICOPATHOLOGICAL STUDY.
Stegall et al. HISTOLOGIC FINDINGS IN RENAL ALLOGRAFTS ONE-YEAR AFTER POSITIVE CROSSMATCH OR ABO INCOMPATIBLE KIDNEY TRANSPLANTATION
Perruche et al. INTRAVENOUS INFUSION OF APOPTOTIC CELLS SIMULTANEOUSLY WITH ALLOGENEIC HEMATOPOIETIC GRAFT ALTERS ANTI-DONOR HUMORAL IMMUNE RESPONSES
Snow et al. EBV+ B CELL LYMPHOMAS ASSOCIATED WITH POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE DEMONSTRATE UNIQUE DEFECTS IN TRAIL-INDUCED APOPTOSIS
Park et al. CLINICAL SIGNIFICANCE OF HUMAN PARVOVIRUS B19 INFECTION IN KIDNEY TRANSPLANT RECIPIENTS
Kawai et al. COMBINED KIDNEY AND BONE MARROW TRANSPLANTATION FOR INDUCTION OF MIXED CHIMERISM AND RENAL ALLOGRAFT TOLERANCE IN HLA MISMATCHED TRANSPLANTATION
Nalesnik et al. POSTTRANSPLANT LYMPHOROLIFERATIVE DISORDERS (PTLD) IN INTESTINAL TRANSPLANT RECIPIENTS
Koehl et al. In Vitro and in Vivo Cyclosporine-Induced Tumor Angiogenesis and Tumor Growth Are Blocked By Simultaneous Application of Rapamycin